LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 60

Search options

  1. Article ; Online: Neuro-Oncology

    Sith Sathornsumetee

    Siriraj Medical Journal, Vol 63, Iss

    An Emerging Neurologic Subspecialty in Thailand

    2020  Volume 5

    Abstract: ... No ... ...

    Abstract No Abstract
    Keywords Neuro-Oncology ; Emerging ; Neurologic ; Thailand ; Medicine (General) ; R5-920
    Language English
    Publishing date 2020-04-01T00:00:00Z
    Publisher Mahidol University
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  2. Article ; Online: Immune checkpoint inhibitor in recurrent hypermutated glioblastoma with

    Sathornsumetee, Sith / Nunta-Aree, Sarun / Cheunsuchon, Pornsuk

    Neuro-oncology advances

    2021  Volume 3, Issue 1, Page(s) vdab093

    Language English
    Publishing date 2021-06-28
    Publishing country England
    Document type Journal Article
    ZDB-ID 3009682-0
    ISSN 2632-2498 ; 2632-2498
    ISSN (online) 2632-2498
    ISSN 2632-2498
    DOI 10.1093/noajnl/vdab093
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Assessment of therapeutic effect of CD20-targeted immunoliposome in primary central nervous system lymphoma.

    Thumrongsiri, Nutthanit / Dana, Paweena / Bawab, Rand / Tanyapanyachon, Prattana / Treetidnipa, Chaichana / Saengkrit, Nattika / Sathornsumetee, Sith

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

    2022  Volume 150, Page(s) 112979

    Abstract: Primary central nervous system lymphoma (PCNSL) is a form of extranodal non-Hodgkin's B-cell lymphoma limited to the CNS. The treatment of PCNSL is ineffective partly due to the blood-brain barrier (BBB) restriction of delivery of many drugs including ... ...

    Abstract Primary central nervous system lymphoma (PCNSL) is a form of extranodal non-Hodgkin's B-cell lymphoma limited to the CNS. The treatment of PCNSL is ineffective partly due to the blood-brain barrier (BBB) restriction of delivery of many drugs including anti-CD20 (Rituximab; RTX) which is a standard treatment for systemic B-cell lymphomas. In this study, liposome with tween-80 surface modification was fabricated and conjugated with RTX for enhancing BBB penetration to target lymphoma cells in the CNS. Physicochemical characterizations of Lip/RTX were performed and spherical shape liposomes with narrow size distribution were demonstrated by TEM. An average diameter of Lip/RTX was 168.57 ± 1.57 nm with the percentage of RTX conjugation at 90.94. Cell internalization monitored by flow cytometry confirmed that conjugation of RTX promoted liposome entry into Raji cells expressing CD20. Antitumor activity of Lip/RTX was comparable to free RTX indicating that RTX moieties on liposome remained their therapeutic function. In addition, Lip/RTX inhibited tumor aggressiveness by limiting cell migration and invasion. Systemic administration of Lip/RTX significantly prolonged survival of mice harboring intracranial lymphoma xenografts. Taken together, Lip/RTX presents a new potential treatment for patients with PCNSL.
    MeSH term(s) Animals ; Antigens, CD20 ; Central Nervous System ; Humans ; Liposomes ; Lymphoma/drug therapy ; Lymphoma, B-Cell/drug therapy ; Mice ; Rituximab/pharmacology ; Rituximab/therapeutic use
    Chemical Substances Antigens, CD20 ; Liposomes ; Rituximab (4F4X42SYQ6)
    Language English
    Publishing date 2022-04-20
    Publishing country France
    Document type Journal Article
    ZDB-ID 392415-4
    ISSN 1950-6007 ; 0753-3322 ; 0300-0893
    ISSN (online) 1950-6007
    ISSN 0753-3322 ; 0300-0893
    DOI 10.1016/j.biopha.2022.112979
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Differential cytokine profiles produced by anti-epileptic drug re-exposure of peripheral blood mononuclear cells derived from severe anti-epileptic drug patients and non-allergic controls.

    Srinoulprasert, Yuttana / Kumkamthornkul, Pongsathorn / Tuchinda, Papapit / Wongwiangjunt, Sattawut / Sathornsumetee, Sith / Jongjaroenprasert, Kowit / Kulthanan, Kanokvalai

    Cytokine

    2022  Volume 157, Page(s) 155951

    Abstract: Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and drug reactions with eosinophilia and systemic symptoms (DRESS) are the most common severe cutaneous adverse drug reactions (SCARs). Anti-epileptic drugs are one of the most common drugs ... ...

    Abstract Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and drug reactions with eosinophilia and systemic symptoms (DRESS) are the most common severe cutaneous adverse drug reactions (SCARs). Anti-epileptic drugs are one of the most common drugs causing SCARs. Cytokine profiles of SCARs during culprit drug exposure have never been characterized. This study aimed to identify cytokine patterns between SCARs and non-SCARs in epilepsy patients and the patterns of DRESS and SJS/TEN. Epilepsy patients that showed allergic responses to anti-epileptic drugs that manifested as SJS/TEN or DRESS were recruited. Epilepsy patients with no drug allergy symptoms and healthy people were also recruited as control groups. Peripheral blood mononuclear cells (PBMCs) were isolated and co-cultured with assigned anti-epileptic drugs according to the lymphocyte transformation test (LTT). LTT and measurement of cytokine levels in supernatants were performed on day six of cell cultivation. This study identified different cytokine expression patterns between SCAR and non-SCAR in epilepsy patients. Significant levels of IL-10, IL-12, IL-17, and GM-CSF were detected in non-SCAR epilepsy. However, the levels of IL-2, IL-5, IL-13, and IFN-gamma were significantly higher in supernatants of PBMCs of DRESS cultivated with AEDs relative to those of SJS/TEN. These cytokine levels were positively correlated with the cell proliferation index. Production of IL-5 and IL-13 was a unique characteristic of DRESS PBMCs. This study was the first to demonstrate distinct differences in cytokine levels between SCAR and non-SCAR PBMCs in epilepsy, which could help explain the immune-pathomechanism of drug hypersensitivity in SCARs. Different patterns of cytokine production and cell proliferation between DRESS and SJS/TEN in AED hypersensitivity were also demonstrated. Production of IL-5 and IL-13 might be a promising marker to define drug hypersensitivity in DRESS.
    MeSH term(s) Cytokines ; Drug Hypersensitivity ; Epilepsy/drug therapy ; Humans ; Interleukin-13 ; Interleukin-5 ; Leukocytes, Mononuclear ; Stevens-Johnson Syndrome/etiology
    Chemical Substances Cytokines ; Interleukin-13 ; Interleukin-5
    Language English
    Publishing date 2022-06-27
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1018055-2
    ISSN 1096-0023 ; 1043-4666
    ISSN (online) 1096-0023
    ISSN 1043-4666
    DOI 10.1016/j.cyto.2022.155951
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Clinical improvements in temporospatial gait variables after a spinal tap test in individuals with idiopathic normal pressure hydrocephalus.

    Bovonsunthonchai, Sunee / Witthiwej, Theerapol / Vachalathiti, Roongtiwa / Hengsomboon, Pichaya / Thong-On, Suthasinee / Sathornsumetee, Sith / Ngamsombat, Chanon / Chawalparit, Orasa / Muangpaisan, Weerasak / Richards, Jim

    Scientific reports

    2024  Volume 14, Issue 1, Page(s) 2053

    Abstract: Idiopathic Normal Pressure Hydrocephalus (iNPH) is a neurological condition that often presents gait disturbance in the early stages of the disease and affects other motor activities. This study investigated changes in temporospatial gait variables after ...

    Abstract Idiopathic Normal Pressure Hydrocephalus (iNPH) is a neurological condition that often presents gait disturbance in the early stages of the disease and affects other motor activities. This study investigated changes in temporospatial gait variables after cerebrospinal fluid (CSF) removal using a spinal tap test in individuals with idiopathic normal pressure hydrocephalus (iNPH), and explored if the tap test responders and non-responders could be clinically identified from temporospatial gait variables. Sixty-two individuals with iNPH were recruited from an outpatient clinic, eleven were excluded, leaving a total of 51 who were included in the analysis. Temporospatial gait variables at self-selected speed were recorded at pre- and 24-h post-tap tests which were compared using Paired t-tests, Cohen's d effect size, and percentage change. A previously defined minimal clinical important change (MCIC) for gait speed was used to determine the changes and to classify tap test responders and non-responders. A mixed model ANOVA was used to determine the within-group, between-group, and interaction effects. Comparisons of the data between pre- and post-tap tests showed significant improvements with small to medium effect sizes for left step length, right step time, stride length and time, cadence, and gait speed. Gait speed showed the largest percentage change among temporospatial gait variables. Within-group and interaction effects were found in some variables but no between-group effect was found. Tap test responders showed significant improvements in right step length and time, stride length and time, cadence, and gait speed while non-responders did not. Some individuals with iNPH showed clinically important improvements in temporospatial gait variables after the tap test, particularly in step/stride length and time, cadence, who could be classified by gait speed. However, gait-related balance variables did not change. Therefore, additional treatments should focus on improving such variables.
    MeSH term(s) Humans ; Spinal Puncture ; Hydrocephalus, Normal Pressure/surgery ; Gait ; Walking Speed ; Ambulatory Care Facilities
    Language English
    Publishing date 2024-01-24
    Publishing country England
    Document type Journal Article
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/s41598-024-52516-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Therapeutic strategies to target multiple kinases in glioblastoma.

    Sathornsumetee, Sith

    Anti-cancer agents in medicinal chemistry

    2011  Volume 11, Issue 8, Page(s) 700–711

    Abstract: Glioblastoma (GBM), the most common primary brain tumor in adults, is one of the most aggressive human cancers associated with high mortality. Standard treatments following diagnosis include surgical resection, radiotherapy and adjunctive chemotherapy. ... ...

    Abstract Glioblastoma (GBM), the most common primary brain tumor in adults, is one of the most aggressive human cancers associated with high mortality. Standard treatments following diagnosis include surgical resection, radiotherapy and adjunctive chemotherapy. However, almost all patients develop disease progression following this multimodal therapy. Recent understanding in genomic and molecular abnormalities in GBM has shifted the treatment paradigm towards using molecularly targeted agents. One of the most prominent targets in cancer treatment is kinases, which can be commonly targeted by small molecule inhibitors or monoclonal antibodies. Despite the initial enthusiasm in exploring kinase inhibitors for GBM, first-generation kinase inhibitors that selectively disrupt single kinases have failed to demonstrate clinical benefit in most patients with GBM. Mechanisms of resistance may include genetic heterogeneity with cross-talk and coactivation of multiple signaling pathways, upregulation of alternative signaling cascades, limited drug delivery and existence of highly-resistant cellular subpopulations such as cancer stem cells. One strategy to circumvent this challenge is to target multiple kinases by multitargeted kinase inhibitors or combinations of single targeted kinase inhibitors, both of which have been evaluated in clinical trials for GBM.
    MeSH term(s) Animals ; Brain Neoplasms/drug therapy ; Brain Neoplasms/enzymology ; Drug Delivery Systems/methods ; Glioblastoma/drug therapy ; Glioblastoma/enzymology ; Humans ; Phosphotransferases/antagonists & inhibitors ; Phosphotransferases/metabolism ; Protein Kinase Inhibitors/administration & dosage
    Chemical Substances Protein Kinase Inhibitors ; Phosphotransferases (EC 2.7.-)
    Language English
    Publishing date 2011-06-25
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 2217610-X
    ISSN 1875-5992 ; 1871-5206
    ISSN (online) 1875-5992
    ISSN 1871-5206
    DOI 10.2174/187152011797378661
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Teaching NeuroImages: Erdheim-Chester disease (polyostotic sclerosing histiocytosis).

    Srivanitchapoom, Prachaya / Sathornsumetee, Sith

    Neurology

    2015  Volume 85, Issue 10, Page(s) e79–80

    MeSH term(s) Adult ; Erdheim-Chester Disease/diagnostic imaging ; Erdheim-Chester Disease/therapy ; Fatal Outcome ; Humans ; Male ; Radiography
    Language English
    Publishing date 2015-09-08
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 207147-2
    ISSN 1526-632X ; 0028-3878
    ISSN (online) 1526-632X
    ISSN 0028-3878
    DOI 10.1212/WNL.0000000000001911
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: Inhibiting Metastasis and Improving Chemosensitivity via Chitosan-Coated Selenium Nanoparticles for Brain Cancer Therapy.

    Dana, Paweena / Pimpha, Nuttaporn / Chaipuang, Angkana / Thumrongsiri, Nutthanit / Tanyapanyachon, Prattana / Taweechaipaisankul, Anukul / Chonniyom, Walailuk / Watcharadulyarat, Natsorn / Sathornsumetee, Sith / Saengkrit, Nattika

    Nanomaterials (Basel, Switzerland)

    2022  Volume 12, Issue 15

    Abstract: Selenium nanoparticles (SeNPs) were synthesized to overcome the limitations of selenium, such as its narrow safe range and low water solubility. SeNPs reduce the toxicity and improve the bioavailability of selenium. Chitosan-coated SeNPs (Cs-SeNPs) were ... ...

    Abstract Selenium nanoparticles (SeNPs) were synthesized to overcome the limitations of selenium, such as its narrow safe range and low water solubility. SeNPs reduce the toxicity and improve the bioavailability of selenium. Chitosan-coated SeNPs (Cs-SeNPs) were developed to further stabilize SeNPs and to test their effects against glioma cells. The effects of Cs-SeNPs on cell growth were evaluated in monolayer and 3D-tumor spheroid culture. Cell migration and cell invasion were determined using a trans-well assay. The effect of Cs-SeNPs on chemotherapeutic drug 5-fluorouracil (5-FU) sensitivity of glioma cells was determined in tumor spheroids. An in vitro blood-brain barrier (BBB) model was established to test the permeability of Cs-SeNPs. SeNPs and Cs-SeNPs can reduce the cell viability of glioma cells in a dose-dependent manner. Compared with SeNPs, Cs-SeNPs more strongly inhibited 3D-tumor spheroid growth. Cs-SeNPs exhibited stronger effects in inhibiting cell migration and cell invasion than SeNPs. Improved 5-FU sensitivity was observed in Cs-SeNP-treated cells. Cellular uptake in glioma cells indicated a higher uptake rate of coumarin-6-labeled Cs-SeNPs than SeNPs. The capability of coumarin-6 associated Cs-SeNPs to pass through the BBB was confirmed. Taken together, Cs-SeNPs provide exceptional performance and are a potential alternative therapeutic strategy for future glioma treatment.
    Language English
    Publishing date 2022-07-29
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2662255-5
    ISSN 2079-4991
    ISSN 2079-4991
    DOI 10.3390/nano12152606
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Brainstem dysfunction heralding disseminated cryptococcosis.

    Srivanitchapoom, Prachaya / Pitakpatapee, Yuvadee / Sitthinamsuwan, Panitta / Sathornsumetee, Sith

    Clinical neurology and neurosurgery

    2018  Volume 167, Page(s) 62–64

    Abstract: Cryptococcal meningoencephalitis is one of the most common central nervous system infections affecting immunocompromised patients. However, brainstem involvement is extremely rare and may represent a diagnostic challenge to clinicians. We report a non- ... ...

    Abstract Cryptococcal meningoencephalitis is one of the most common central nervous system infections affecting immunocompromised patients. However, brainstem involvement is extremely rare and may represent a diagnostic challenge to clinicians. We report a non-HIV infected, chronically immunosuppressed, patient with fatal disseminated cryptococcosis presented with subcutaneous masses at both thighs and progressive brainstem dysfunction. Magnetic resonance imaging demonstrated multiple brainstem infarcts likely derived from small vessel vasculopathy. Anti-fungal treatment led to partial neurologic improvement but the patient succumbed to a fatal sepsis from hospital-acquired pneumonia.
    MeSH term(s) Antifungal Agents/therapeutic use ; Brain Diseases/drug therapy ; Brain Diseases/pathology ; Brain Stem/physiopathology ; Cryptococcosis/diagnosis ; Cryptococcosis/drug therapy ; Cryptococcosis/pathology ; Female ; Humans ; Immunocompromised Host/drug effects ; Magnetic Resonance Imaging/methods ; Meningoencephalitis/drug therapy ; Meningoencephalitis/pathology ; Middle Aged ; Treatment Outcome
    Chemical Substances Antifungal Agents
    Language English
    Publishing date 2018-02-12
    Publishing country Netherlands
    Document type Case Reports ; Journal Article
    ZDB-ID 193107-6
    ISSN 1872-6968 ; 0303-8467
    ISSN (online) 1872-6968
    ISSN 0303-8467
    DOI 10.1016/j.clineuro.2018.02.015
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Exploiting nanopore sequencing for characterization and grading of IDH-mutant gliomas.

    Wongsurawat, Thidathip / Jenjaroenpun, Piroon / Anekwiang, Panatna / Arigul, Tantip / Thongrattana, Wichayapat / Jamshidi-Parsian, Azemat / Boysen, Gunnar / Suriyaphol, Prapat / Suktitipat, Bhoom / Srirabheebhat, Prajak / Cheunsuchon, Pornsuk / Tanboon, Jantima / Nookaew, Intawat / Sathornsumetee, Sith

    Brain pathology (Zurich, Switzerland)

    2023  Volume 34, Issue 1, Page(s) e13203

    Abstract: The 2021 WHO Classification of Central Nervous System Tumors recommended evaluation of cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) deletion in addition to codeletion of 1p/19q to characterize IDH-mutant gliomas. Here, we demonstrated the use of a ... ...

    Abstract The 2021 WHO Classification of Central Nervous System Tumors recommended evaluation of cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) deletion in addition to codeletion of 1p/19q to characterize IDH-mutant gliomas. Here, we demonstrated the use of a nanopore-based copy-number variation sequencing (nCNV-seq) approach to simultaneously identify deletions of CDKN2A/B and 1p/19q. The nCNV-seq approach was initially evaluated on three distinct glioma cell lines and then applied to 19 IDH-mutant gliomas (8 astrocytomas and 11 oligodendrogliomas) from patients. The whole-arm 1p/19q codeletion was detected in all oligodendrogliomas with high concordance among nCNV-seq, FISH, DNA methylation profiling, and whole-genome sequencing. For the CDKN2A/B deletion, nCNV-seq detected the loss in both astrocytoma and oligodendroglioma, with strong correlation with the CNV profiles derived from whole-genome sequencing (Pearson correlation (r) = 0.95, P < 2.2 × 10
    MeSH term(s) Humans ; Oligodendroglioma/genetics ; Oligodendroglioma/pathology ; Brain Neoplasms/pathology ; Nanopore Sequencing ; Mutation ; Glioma/pathology ; Astrocytoma/pathology ; Isocitrate Dehydrogenase/genetics ; Chromosomes, Human, Pair 1 ; Chromosomes, Human, Pair 19
    Chemical Substances Isocitrate Dehydrogenase (EC 1.1.1.41)
    Language English
    Publishing date 2023-08-13
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ZDB-ID 1051484-3
    ISSN 1750-3639 ; 1015-6305
    ISSN (online) 1750-3639
    ISSN 1015-6305
    DOI 10.1111/bpa.13203
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top